MCID: EXN002
MIFTS: 62

Exanthem

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Exanthem

Summaries for Exanthem

MedlinePlus : 40 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to aseptic meningitis and cryopyrin-associated periodic syndrome. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 An exanthem or exanthema (from Greek ἐξάνθημα exánthēma, \"a breaking out\") is a widespread rash... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 aseptic meningitis 30.5 IL1RN NLRP3 TNF
2 cryopyrin-associated periodic syndrome 30.2 CRP IL1RN NLRP3
3 meningoencephalitis 30.2 CD40LG CD79A TLR9
4 meningitis 30.2 CD40LG CRP NLRP3 TLR9 TNF
5 pneumonia 30.1 CD40LG CRP TLR9 TNF
6 myeloma, multiple 30.0 CD40LG CD79A HRAS TLR9
7 acquired immunodeficiency syndrome 29.6 CD40LG CD79A IL2 TNF
8 mumps 29.5 CD40LG IL2 TNFRSF1A
9 brucellosis 29.3 CD40LG CRP IL1RN IL2 TNF
10 exanthema subitum 12.3
11 viral exanthem 12.1
12 bacterial exanthem 11.9
13 hand, foot and mouth disease 11.3
14 contagious pustular dermatitis 11.0
15 severe cutaneous adverse reaction 11.0
16 selective igg deficiency disease 10.7 CD40LG CD79A
17 c1q nephropathy 10.7 CD40LG CD79A
18 meningovascular neurosyphilis 10.6 CD40LG CD79A
19 alpha chain disease 10.6 CD40LG CD79A
20 brill-zinsser disease 10.6 CD40LG CD79A
21 exudative glomerulonephritis 10.6 CD40LG CD79A
22 cork-handlers' disease 10.6 CD40LG CD79A
23 salpingo-oophoritis 10.6 CD40LG CD79A
24 breast intraductal proliferative lesion 10.6 EGFR ERBB2
25 early yaws 10.6 CD40LG CD79A
26 ventilation pneumonitis 10.6 CD40LG CD79A
27 chronic interstitial cystitis 10.6 CD40LG CD79A
28 axillary adenitis 10.6 CD40LG CD79A
29 cryofibrinogenemia 10.6 CD40LG CD79A
30 sigmoid neoplasm 10.6 HRAS KRAS
31 schnitzler syndrome 10.6 CD40LG IL1RN NLRP3
32 transient neonatal thrombocytopenia 10.5 CD79A TRIM21
33 ocular toxoplasmosis 10.5 CD40LG CD79A TLR9
34 conjunctival disease 10.5 CD40LG CD79A NLRP3
35 trichostrongyloidiasis 10.5 CD40LG CD79A
36 autoimmune disease of urogenital tract 10.5 CD40LG CD79A TLR9
37 subacute bacterial endocarditis 10.5 CD40LG CD79A
38 acute maxillary sinusitis 10.5 CD40LG CD79A CRP
39 hypersensitivity vasculitis 10.5 CD40LG CD79A CRP
40 intussusception 10.5 CD40LG CD79A CRP
41 heterophyiasis 10.5 CD40LG CD79A
42 hypersensitivity reaction type iii disease 10.5 CD40LG CD79A CRP
43 pyelitis 10.5 CD40LG CD79A CRP
44 lung adenoid cystic carcinoma 10.5 EGFR HRAS KRAS
45 mature b-cell neoplasm 10.5 CD40LG CD79A TLR9
46 immunoglobulin g deficiency 10.5 CD40LG CD79A
47 b cell deficiency 10.5 CD40LG CD79A TLR9
48 endocardium disease 10.5 CD40LG CD79A CRP
49 tumor suppressor gene on chromosome 11 10.5 EGFR ERBB2 KRAS
50 anterior scleritis 10.5 CD79A IL1RN TNFRSF1B

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

25 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.4 HRAS EGFR KALRN KRAS MTOR
2 Decreased viability GR00106-A-0 10.4 KRAS
3 Decreased viability GR00221-A-1 10.4 HRAS KALRN KRAS MTOR MAP2K7 EGFR
4 Decreased viability GR00221-A-2 10.4 HRAS KALRN KRAS
5 Decreased viability GR00221-A-3 10.4 HRAS
6 Decreased viability GR00221-A-4 10.4 KALRN MTOR EGFR
7 Decreased viability GR00301-A 10.4 KALRN KRAS
8 Decreased viability GR00342-S-1 10.4 KALRN MTOR MAP2K7
9 Decreased viability GR00342-S-2 10.4 KALRN MTOR
10 Decreased viability GR00342-S-3 10.4 KALRN
11 Decreased viability GR00381-A-1 10.4 KALRN KRAS
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR ERBB2 HRAS HSPG2 KALRN MTOR
13 Decreased cell migration GR00055-A-1 9.72 EGFR HRAS KALRN KRAS MTOR
14 Decreased substrate adherent cell growth GR00193-A-2 9.55 EGFR KALRN MAP2K7 MTOR
15 Decreased substrate adherent cell growth GR00193-A-3 9.55 MAP2K7
16 Decreased viability with paclitaxel GR00179-A-1 9.36 ERBB2 MTOR EGFR
17 Decreased viability with paclitaxel GR00179-A-2 9.36 MTOR
18 Decreased viability with paclitaxel GR00179-A-3 9.36 EGFR MTOR

MGI Mouse Phenotypes related to Exanthem:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.54 HSPG2 IL1RN IL2 KALRN KRAS MAP2K7
2 cellular MP:0005384 10.48 CD40LG CD79A EGFR ERBB2 HSPG2 IL1RN
3 cardiovascular system MP:0005385 10.46 EGFR ERBB2 HRAS HSPG2 IL1RN IL2
4 hematopoietic system MP:0005397 10.44 CD40LG CD79A EGFR HSPG2 IL1RN IL2
5 immune system MP:0005387 10.42 CD79A CRP EGFR HSPG2 IL1RN IL2
6 mortality/aging MP:0010768 10.42 EGFR ERBB2 HRAS HSPG2 IL1RN IL2
7 growth/size/body region MP:0005378 10.39 MTOR NLRP3 TNF TNFRSF1A TNFRSF1B EGFR
8 integument MP:0010771 10.38 CD40LG EGFR ERBB2 HRAS HSPG2 IL1RN
9 behavior/neurological MP:0005386 10.36 TNF TNFRSF1A TNFRSF1B ERBB2 HRAS HSPG2
10 endocrine/exocrine gland MP:0005379 10.36 KRAS MAP2K7 MTOR TNF TNFRSF1A TNFRSF1B
11 digestive/alimentary MP:0005381 10.33 EGFR ERBB2 HRAS HSPG2 IL2 KRAS
12 nervous system MP:0003631 10.28 ERBB2 HRAS HSPG2 KALRN KRAS MAP2K7
13 craniofacial MP:0005382 10.2 EGFR ERBB2 HRAS HSPG2 KRAS TNF
14 liver/biliary system MP:0005370 10.16 CD79A EGFR HSPG2 IL2 KRAS NLRP3
15 neoplasm MP:0002006 10.16 TNF TNFRSF1A TNFRSF1B CD79A EGFR ERBB2
16 muscle MP:0005369 10.13 EGFR ERBB2 HSPG2 KALRN KRAS MTOR
17 limbs/digits/tail MP:0005371 10.07 EGFR ERBB2 HSPG2 KRAS NLRP3 TNF
18 no phenotypic analysis MP:0003012 10.06 MTOR TNF TNFRSF1A CD79A EGFR HRAS
19 renal/urinary system MP:0005367 10.06 CD40LG CD79A EGFR HRAS KRAS MTOR
20 normal MP:0002873 10.02 CD79A EGFR ERBB2 HRAS KALRN KRAS
21 reproductive system MP:0005389 10 CD40LG EGFR ERBB2 IL1RN IL2 KALRN
22 respiratory system MP:0005388 9.85 TNFRSF1A TNFRSF1B EGFR ERBB2 HRAS HSPG2
23 skeleton MP:0005390 9.73 CD40LG EGFR ERBB2 HRAS HSPG2 IL1RN
24 vision/eye MP:0005391 9.23 EGFR HSPG2 IL2 KRAS MAP2K7 TNF

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 940)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
5
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
6
Zinc oxide Approved Phase 4,Phase 3 1314-13-2
7
Apraclonidine Approved Phase 4,Phase 3 66711-21-5 2216
8
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
9
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
10
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
11
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
13
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2 94-36-0 7187
14
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 18323-44-9 29029
15
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
16
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
17 sodium fluoride Approved Phase 4,Phase 2 7681-49-4
18
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
19
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-72-7 338
20
Sorafenib Approved, Investigational Phase 4,Phase 2 284461-73-0 216239 406563
21
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 25122-41-2, 25122-46-7 5311051 32798
22
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 124-94-7 31307
23
Rifampin Approved Phase 4,Phase 1,Phase 2 13292-46-1 5381226 5458213
24
Sunitinib Approved, Investigational Phase 4,Phase 1 341031-54-7, 557795-19-4 5329102
25
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 83905-01-5 53477736 447043 55185
26
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1 154598-52-4 64139
27
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1 137-58-6 3676
28
Petrolatum Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 8009-03-8
29
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 564-25-0 54671203
30
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Phase 2 103-90-2 1983
31
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
32
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
33
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 1994-09-7, 94-09-7 2337
34
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
35
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
36
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2 378-44-9 9782
37
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 137071-32-0 17753757 6447131
38
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
39
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
40
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2 608141-41-9 11561674
41
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 198153-51-4 5360545
42
Ribavirin Approved Phase 4,Phase 3,Phase 1 36791-04-5 37542
43
Artemether Approved Phase 4,Phase 2,Phase 3,Phase 1 71963-77-4 68911 119380
44
Lumefantrine Approved Phase 4,Phase 2,Phase 3,Phase 1 82186-77-4 6437380
45
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
46
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
47
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
48
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
49
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
50
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 1872)

# Name Status NCT ID Phase Drugs
1 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
2 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
3 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
5 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
6 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
7 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
8 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
9 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
10 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
11 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
12 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
13 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
14 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
15 Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash Completed NCT00219466 Phase 4
16 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
17 Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
18 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
19 Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients Completed NCT02184299 Phase 4 Nevirapine;Prednisone
20 Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot Completed NCT02742285 Phase 4 Artemether + lumefantrine
21 Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study Completed NCT00723515 Phase 4 sodium fluoride;sodium fluoride calcium fluoride
22 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
23 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
24 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
25 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4 Tretinoin cream 0.05
26 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
27 Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. Completed NCT01195194 Phase 4 PRE-TRANSPLANT (PRE=before)
28 Efficacy of Pentoxifylline on Chronic Kidney Disease Completed NCT00155246 Phase 4 pentoxifylline (drug)
29 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
30 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
31 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
32 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
33 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
34 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
35 Bipolar Study in Adults at Least 18 Years of Age Completed NCT00067938 Phase 4 lamotrigine
36 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep Completed NCT00168857 Phase 4 telmisartan;losartan
37 FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra Completed NCT01656148 Phase 4 Fampridine-SR
38 Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women Completed NCT00616239 Phase 4 20-30% Salicylic Acid peels to the right side of the face;20-30% Salicylic Acid peels to the left side of the face
39 Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients Completed NCT00882089 Phase 4
40 Oral Contraceptive Efficacy and Body Weight Completed NCT00662454 Phase 4 ethinyl estradiol / levonorgestrel;ethinyl estradiol / levonorgestrel
41 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
42 A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Completed NCT02143882 Phase 4 Fluenz
43 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
44 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
45 Prednisolone Pharmacokinetics in Severe Asthma Completed NCT00662298 Phase 4 prednisolone
46 Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Completed NCT00232232 Phase 4 Fish oil
47 NOW Thai HAART Study Completed NCT00367731 Phase 4 Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)
48 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
49 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
50 Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis Completed NCT00617643 Phase 4 Nevirapine without dose escalation;Nevirapine initiation with dose escalation

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

38
Skin, Testes, Lung, Kidney, Eye, Bone, Brain

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 263)
# Title Authors Year
1
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
2
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )
2018
3
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )
2018
4
Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )
2018
5
Unilateral laterothoracic exanthem. ( 28754336 )
2017
6
Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )
2017
7
Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )
2017
8
Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )
2017
9
Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )
2017
10
Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )
2017
11
Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )
2017
12
Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )
2017
13
Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )
2017
14
IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )
2017
15
TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )
2017
16
Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )
2016
17
A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )
2016
18
Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )
2016
19
Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )
2016
20
Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )
2016
21
Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )
2016
22
"Tache noire": diagnostic clue in a febrile exanthem. ( 28038854 )
2016
23
Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )
2016
24
Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )
2016
25
Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )
2016
26
Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )
2016
27
Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )
2016
28
Purpuric exanthem caused by Ross River virus infection. ( 25551310 )
2015
29
Febrile Exanthem with Hyperferritinemia. ( 26705442 )
2015
30
Localized exanthem due to echovirus 9. ( 25919440 )
2015
31
Unilateral Laterothoracic Exanthem. ( 26187001 )
2015
32
Unilateral Exanthem. ( 26120168 )
2015
33
Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )
2014
34
Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )
2014
35
Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )
2014
36
Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )
2014
37
Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )
2014
38
Black heel (talon noir) associated with a viral exanthem. ( 24222298 )
2013
39
Unilateral laterothoracic exanthem. ( 21989468 )
2012
40
Acetaminophen-induced exanthem of the breasts. ( 22838093 )
2012
41
Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )
2012
42
Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )
2012
43
Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )
2012
44
Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )
2012
45
Drug-induced exanthem following dabigatran. ( 21881034 )
2011
46
Asymmetrical periflexural exanthem of childhood with concurrence of molluscum contagiosum infection. ( 21457157 )
2011
47
A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )
2011
48
Papular exanthem discloses acute myeloid leukaemia: interphase fluorescence in situ hybridization revealed deletion of p53 and gain at 8q22/8q24/Tel8q without trisomy 8. ( 19438543 )
2010
49
Transient linear eruption: asymmetric periflexural exanthem or blaschkitis. ( 20609153 )
2010
50
Image in medicine. An exanthem with an annular pattern in a 2-year-old girl. Atypical viral exanthem with an annular pattern. ( 20838712 )
2010

Variations for Exanthem

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CD40LG EGFR ERBB2 HRAS HSPG2 IL2
2
Show member pathways
13.74 CD40LG EGFR ERBB2 HRAS IL2 KRAS
3
Show member pathways
13.64 EGFR ERBB2 HRAS IL2 KRAS MAP2K7
4
Show member pathways
13.55 CD40LG CD79A EGFR ERBB2 HRAS KRAS
5
Show member pathways
13.4 CD40LG EGFR ERBB2 HRAS IL2 KRAS
6
Show member pathways
13.36 EGFR ERBB2 HRAS IL2 KRAS TNF
7
Show member pathways
13.33 CD40LG EGFR ERBB2 HRAS IL1RN IL2
8
Show member pathways
13.31 CD40LG EGFR ERBB2 HRAS IL2 KRAS
9
Show member pathways
13.16 CD79A EGFR HRAS HSPG2 IL2 KRAS
10
Show member pathways
13.15 CD40LG CD79A CRP EGFR ERBB2 HRAS
11
Show member pathways
13.13 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
12
Show member pathways
13.1 CD79A EGFR ERBB2 HRAS IL2 KRAS
13
Show member pathways
13.07 EGFR HRAS IL2 KRAS MTOR TNF
14
Show member pathways
13.02 EGFR HRAS IL1RN KRAS MAP2K7 NLRP3
15
Show member pathways
12.97 HRAS KRAS MAP2K7 TNF TNFRSF1A TNFRSF1B
16
Show member pathways
12.96 CD79A EGFR HRAS KRAS TNF TNFRSF1A
17 12.94 EGFR ERBB2 HRAS IL2 KRAS MTOR
18
Show member pathways
12.9 IL2 MAP2K7 NLRP3 TLR9 TNF TNFRSF1A
19
Show member pathways
12.86 HRAS IL2 KRAS MTOR TNF TNFRSF1A
20 12.85 EGFR HRAS KRAS MAP2K7 TNF TNFRSF1A
21
Show member pathways
12.84 EGFR ERBB2 HRAS KRAS MTOR
22
Show member pathways
12.83 CD79A EGFR ERBB2 HRAS KRAS MTOR
23
Show member pathways
12.8 ERBB2 HRAS KRAS MAP2K7 MTOR
24
Show member pathways
12.75 EGFR HRAS KRAS MAP2K7 MTOR
25
Show member pathways
12.74 CD40LG EGFR IL2 TLR9 TNF TNFRSF1A
26
Show member pathways
12.7 EGFR ERBB2 HRAS IL2 KRAS TNF
27
Show member pathways
12.69 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
28
Show member pathways
12.68 CD79A HRAS KRAS MAP2K7 TNF
29
Show member pathways
12.67 CD40LG HRAS MAP2K7 TLR9 TNF TNFRSF1A
30
Show member pathways
12.64 IL2 MAP2K7 TLR9 TNF TNFRSF1A
31 12.62 EGFR ERBB2 HRAS KRAS MTOR
32
Show member pathways
12.62 CD40LG CD79A HRAS IL2 MAP2K7 TNF
33
Show member pathways
12.6 CD40LG EGFR HRAS KRAS MAP2K7 TNF
34
Show member pathways
12.59 ERBB2 HRAS IL1RN KRAS MTOR
35
Show member pathways
12.59 HRAS HSPG2 KRAS MAP2K7 MTOR TNF
36
Show member pathways
12.58 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
37
Show member pathways
12.55 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
38 12.52 HRAS IL2 KRAS TNF TNFRSF1A
39
Show member pathways
12.52 EGFR ERBB2 HRAS IL2 KRAS MTOR
40
Show member pathways
12.5 CD40LG HRAS IL2 KRAS MAP2K7 TNF
41
Show member pathways
12.44 EGFR HRAS IL2 MTOR
42
Show member pathways
12.42 HRAS HSPG2 KRAS MTOR
43
Show member pathways
12.41 MAP2K7 TNF TNFRSF1A TNFRSF1B
44
Show member pathways
12.39 EGFR ERBB2 HRAS KRAS
45 12.37 CD40LG CD79A IL1RN IL2 TLR9 TNF
46
Show member pathways
12.33 HRAS KRAS MAP2K7 MTOR
47 12.33 CD40LG TNF TNFRSF1A TNFRSF1B
48
Show member pathways
12.33 EGFR ERBB2 HRAS KRAS MTOR
49
Show member pathways
12.31 EGFR HRAS KRAS MAP2K7
50 12.3 EGFR KRAS TLR9 TNF TNFRSF1A

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 CD40LG CRP EGFR HSPG2 IL1RN IL2
2 extracellular region GO:0005576 9.7 CD40LG CRP EGFR HSPG2 IL1RN IL2
3 membrane raft GO:0045121 9.1 CD79A EGFR KRAS TNF TNFRSF1A TNFRSF1B

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.96 EGFR TNF TNFRSF1A TNFRSF1B
2 MAPK cascade GO:0000165 9.88 EGFR ERBB2 HRAS IL2 KRAS TNF
3 positive regulation of protein kinase B signaling GO:0051897 9.87 EGFR ERBB2 MTOR TNF
4 positive regulation of cell growth GO:0030307 9.85 EGFR ERBB2 IL2
5 cell surface receptor signaling pathway GO:0007166 9.85 CD79A EGFR ERBB2 HRAS TNFRSF1A TNFRSF1B
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.84 CD40LG TNF TNFRSF1A TNFRSF1B
7 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.83 NLRP3 TLR9 TRIM21
8 positive regulation of JNK cascade GO:0046330 9.83 HRAS TLR9 TNF
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 CD40LG KRAS NLRP3 TLR9 TNF
10 response to glucocorticoid GO:0051384 9.81 IL1RN KRAS TNF
11 positive regulation of epithelial cell proliferation GO:0050679 9.8 EGFR ERBB2 HRAS
12 positive regulation of gene expression GO:0010628 9.8 CRP ERBB2 HRAS KRAS MTOR TLR9
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 EGFR MTOR TNF
14 epidermal growth factor receptor signaling pathway GO:0007173 9.79 EGFR HRAS KRAS
15 negative regulation of inflammatory response GO:0050728 9.78 IL2 NLRP3 TNFRSF1A TNFRSF1B
16 cellular response to growth factor stimulus GO:0071363 9.77 EGFR ERBB2 TNFRSF1B
17 cellular response to amino acid stimulus GO:0071230 9.77 EGFR MTOR TNF
18 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.76 TNF TNFRSF1A TNFRSF1B
19 positive regulation of